We are live on ! Find out more
AP

Atwood & Palmer Portfolio holdings

AUM $1.87B
1-Year Est. Return 24.22%
This Fund
S&P 500
This Quarter Est. Return
+5.61%
1 Year Est. Return
+24.22%
3 Year Est. Return
+82.33%
5 Year Est. Return
+97.89%
10 Year Est. Return
+352.71%
AUM
$626M
AUM Growth
+$69.8M
Cap. Flow
+$41.9M
Cap. Flow %
6.69%
Top 10 Hldgs %
36.72%
Holding
359
New
25
Increased
41
Reduced
79
Closed
62
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACUR
351
DELISTED
Acura Pharmaceuticals
ACUR
-1,010
Closed -$1K
IIP
352
DELISTED
INTERNAP NETWORK SERVICES CORPORATION
IIP
$0 ﹤0.01%
1
YELL
353
DELISTED
Yellow Corporation Common Stock
YELL
$0 ﹤0.01%
3
BDSI
354
DELISTED
BioDelivery Sciences International, Inc.
BDSI
-2,000
Closed -$4K
BCR
355
DELISTED
CR Bard Inc.
BCR
-27
Closed -$6K
NTT
356
DELISTED
Nippon Telegraph & Telephone
NTT
-123
Closed -$5K
ACAS
357
DELISTED
American Capital Ltd
ACAS
-1,332
Closed -$24K
EDE
358
DELISTED
Empire District Electric
EDE
-250
Closed -$9K
PARN
359
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
-16,900
Closed -$12K

Similar funds

Atwood & Palmer's Q1 2017 Portfolio in Review

As of Q1 2017, Atwood & Palmer held 359 positions worth $626M, up 13% from $556M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Atwood & Palmer deployed $41.9M of net new capital in Q1 2017, opening 25 new positions and adding to 41 existing holdings. Its largest new stake was VelocityShares VIX Tail Risk ETN: 900,445 shares worth $20.6M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 26% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Novo Nordisk, an estimated $5.71M trimmed.

  • Atwood & Palmer's largest Q1 2017 buy was VelocityShares VIX Tail Risk ETN: 900,445 shares worth $20.6M.
  • Atwood & Palmer added most to First Trust Dorsey Wright International Focus 5 ETF in Q1 2017, an estimated $22M increase.
  • Atwood & Palmer's biggest Q1 2017 reduction was Novo Nordisk, cutting an estimated $5.71M.
  • Atwood & Palmer fully exited First Trust Consumer Discretionary AlphaDEX Fund in Q1 2017, selling an estimated $1.44M.
  • Atwood & Palmer's ten largest holdings make up 37% of its $626M portfolio in Q1 2017.
  • Atwood & Palmer opened 25 new positions and closed 62 in Q1 2017.
  • Atwood & Palmer's portfolio value rose 13% quarter-over-quarter to $626M.

Based on Atwood & Palmer's 13F filing for Q1 2017, filed 28 Apr 2017.